6-bromo-4-methylquinazolin-2-amine | 1552301-65-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-bromo-4-methylquinazolin-2-amine
• CAS: 1552301-65-1
• 化学式: C₉H₈BrN₃
• 分子量: 238.087
• InChiKey: ZRJPAOVZGMUSNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4-二氟-n-[2-甲氧基-5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-3-吡啶]-苯磺酰胺 、 6-bromo-4-methylquinazolin-2-amine 在 双三苯基磷二氯化钯 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以67%的产率得到N-(5-(2-amino-4-methylquinazolin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide
  参考文献：
  名称：

  Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors

  摘要：

  Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin ( mTOR) signaling pathway is one of the most intensively studied approaches to cancer therapy. Rational design led to the identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors. Design, synthesis and structure activity relationship are reported. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.112
• 作为产物：
  描述：

  2-氨基-5-溴-N-甲氧基-N-甲基苯甲酰胺 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.58h， 生成 6-bromo-4-methylquinazolin-2-amine
  参考文献：
  名称：

  Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors

  摘要：

  Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin ( mTOR) signaling pathway is one of the most intensively studied approaches to cancer therapy. Rational design led to the identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors. Design, synthesis and structure activity relationship are reported. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.112

文献信息

• [EN] CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF<br/>[FR] ENTITÉS CHIMIQUES ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：INTELLIKINE INC

  公开号：WO2009046448A1

  公开（公告）日：2009-04-09

  Certain chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with PB kinase activity are described.

  本文描述了调节PI3激酶活性的某些化学实体，以及与PB激酶活性相关的疾病和病症的化学实体、制药组合物和治疗方法。
• CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF
  申请人：Ren Pingda

  公开号：US20110160232A1

  公开（公告）日：2011-06-30

  Certain chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with PB kinase activity are described.
• CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF
  申请人：Intellikine, LLC.

  公开号：US20140350248A1

  公开（公告）日：2014-11-27

  Certain chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with PB kinase activity are described.
• US9359349B2
  申请人：——

  公开号：US9359349B2

  公开（公告）日：2016-06-07
• Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors
  作者：Songwen Lin、Fangbin Han、Peng Liu、Jing Tao、Xuechao Zhong、Xiujie Liu、Chongqin Yi、Heng Xu

  DOI：10.1016/j.bmcl.2013.12.112

  日期：2014.2

  Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin ( mTOR) signaling pathway is one of the most intensively studied approaches to cancer therapy. Rational design led to the identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors. Design, synthesis and structure activity relationship are reported. (C) 2013 Elsevier Ltd. All rights reserved.